Asset Details
Do you wish to reserve the book?
Incidence and risk factors of sarcopenia in gastric cancer patients: a meta-analysis and systematic review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Incidence and risk factors of sarcopenia in gastric cancer patients: a meta-analysis and systematic review
Do you wish to request the book?
Incidence and risk factors of sarcopenia in gastric cancer patients: a meta-analysis and systematic review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Incidence and risk factors of sarcopenia in gastric cancer patients: a meta-analysis and systematic review
2025
Overview
Background
This meta-analysis was to assess the incidence and risk factors of sarcopenia in gastric cancer (GC) patients and to provide clinical implications for the prevention and improvement of sarcopenia in GC patients.
Methods
PubMed, Embase, Cochrane, Web of Science, CNKI, Wanfang, and VIP databases (language was limited to Chinese and English) were searched for observational studies. The random-effects model was used to analyze the incidence of GC combined with sarcopenia and the odd ratio (OR) and 95% confidence interval (CI) of risk factors.
Results
1244 studies were retrieved and 20 eligible studies were included. The meta-analysis revealed that the incidence of sarcopenia in GC patients was 26.6% (95% CI: 21%~32%). Age (OR = 1.128, 95% CI: 1.056 ~ 1.204,
P
< 0.001), male (OR = 1.054, 95% CI: 0.620 ~ 1.791,
P
< 0.005), body mass index (OR = 1.117, 95% CI: 0.881 ~ 1.414,
P
< 0.001), nutritional risk screening 2002 (OR = 3.953, 95% CI: 2.038 ~ 7.668,
P
< 0.05), and tumor diameter > 3 cm (OR = 1.515, 95% CI: 1.021 ~ 2.248,
P
< 0.05) may be risk factors for sarcopenia in GC patients. In contrast, tumor stage (OR = 1.907, 95% CI: 0.967 ~ 3.763,
P
> 0.05), gastrectomy approach (OR = 1.837, 95% CI: 1.237 ~ 2.727,
P
> 0.05), differentiation type (OR = 0.586, 95%CI: 0.325 ~ 1.059,
P
> 0.05), and severe adverse reactions (NLR, HB, ALB) after chemotherapy (OR = 0.926, 95%CI: 0.793 ~ 1.082,
P
> 0.05) had no significant correlation with sarcopenia in GC patients.
Conclusions
This meta-analysis shows an increased prevalence of sarcopenia in GC patients. This analysis, which focused on Asian populations, suggested that high nutritional risk was a risk factor for sarcopenia in GC patients. Age over 65 years and tumor diameter over 3 cm may be risk factors for sarcopenia. Men may be prone to sarcopenia. Targeting these risk factors may be beneficial in the prevention of sarcopenia in GC patients.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Analysis
/ Biomedical and Life Sciences
/ Cancer
/ Complications and side effects
/ Female
/ Health Promotion and Disease Prevention
/ Humans
/ Male
/ Oncology
/ Prevalence studies (Epidemiology)
/ Stomach Neoplasms - complications
/ Stomach Neoplasms - epidemiology
/ Stomach Neoplasms - pathology
/ Tumors
